Professor Graham Cookson responds to President Donald Trump's Executive Order on drug prices published earlier this week.

GLP-1 receptor agonists are reshaping obesity care. OHE highlights access challenges, prescribing policy, and how patient and ...

Dimitrios is an economist and his research interests lie in the fields of the economics of innovation and specifically on the economics of pharmaceutical markets and R&D. In addition, he is interested ...

Long-acting therapies offer value for chronic disease, improving adherence and outcomes. This OHE report highlights HTA gaps, ...

Laura Vallejo-Torres is Associate Professor at the University of Las Palmas de Gran Canaria, Spain. She holds an MSc in Health Economics from the University of York and a Ph.D. in Health Economics ...

The National Institute for Health and Care Excellence (NICE) is the body responsible for recommending medicines for use within the National Health Service (NHS) in England. High Proportion of ...

Kelsey joined OHE in March 2025 as an External Engagement Officer. She holds a BA degree in Psychology from the University of Chicago and an MSc Public Health (Health Promotion) from the London School ...

Immunisation programmes are foundational to public health. Organised by health authorities, they systematically deliver vaccines to susceptible populations to prevent the spread of infectious diseases ...

Health Technology Assessment (HTA) agencies evaluate and make decisions on the use, funding, or reimbursement of health technologies based on clinical and economic evidence. Economic evaluations can ...

Dr Richard Torbett joined ABPI in July 2015 and previously held the role of Executive Director of Economic, Health and Commercial Policy. In this role, Richard was responsible for pricing policy ...